The article from WIRED discusses the surge of off-brand oral versions of GLP-1 drugs like Ozempic being sold online, especially after shortages of the injectable forms began in 2022. These compounded versions, sold by telehealth companies and pharmacies, promise similar active ingredients in a more accessible oral format at lower prices. However, experts express skepticism about their efficacy and safety, highlighting that most of these formulations haven't undergone rigorous clinical testing and lack FDA approval. The article explains challenges related to oral administration of large molecule drugs like GLP-1s, concerns over absorption, and the importance of sourcing compounded medications from accredited pharmacies.

Key Points:

• GLP-1 drugs like Ozempic are in high demand for treating diabetes, obesity, and various other conditions, leading to injectable shortages.
• Oral versions are being marketed online at much lower prices, promising similar benefits without injections.
• There is skepticism among healthcare professionals regarding the efficacy and safety of compounded oral GLP-1s, as they lack FDA approval and rigorous testing.
• The complexity of formulating oral versions of GLP-1 drugs is underscored by the need for absorption enhancers due to the drugs' large molecular structure.
• Only one FDA-approved oral GLP-1 drug exists: Rybelsus, but it is less popular and has not been approved for weight loss.
• Consumers are urged to purchase such medications only from accredited pharmacies to ensure safety and quality.
  Link to Article